These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22453190)

  • 21. Berlex continues legal challenge to FDA over MS drug.
    Glaser V
    Nat Biotechnol; 1996 Jul; 14(7):811-2. PubMed ID: 9630997
    [No Abstract]   [Full Text] [Related]  

  • 22. Orphan drug regulations. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2013 Jun; 78(113):35117-35. PubMed ID: 23767079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Orphan drugs and orphan tests in the USA.
    Thoene JG
    Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190
    [No Abstract]   [Full Text] [Related]  

  • 24. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2011 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
    [No Abstract]   [Full Text] [Related]  

  • 27. FDA launches priority vouchers for neglected-disease drugs.
    Waltz E
    Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
    [No Abstract]   [Full Text] [Related]  

  • 28. Orphan drug development in the United States.
    Groft SC
    CPJ; 1985 May; 118(5):219-22. PubMed ID: 10271306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical studies of safety and effectiveness of orphan products; availability of grants; request for applications--FDA. Notice.
    Fed Regist; 1998 Aug; 63(150):41855-9. PubMed ID: 10181724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative analysis to guide orphan drug development.
    Lesko LJ
    Clin Pharmacol Ther; 2012 Aug; 92(2):258-61. PubMed ID: 22739138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
    Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
    Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases.
    Xu K; Coté TR
    Brief Bioinform; 2011 Jul; 12(4):341-5. PubMed ID: 21357612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Orphan drug development: the increasing role of clinical pharmacology.
    Ahmed MA; Okour M; Brundage R; Kartha RV
    J Pharmacokinet Pharmacodyn; 2019 Oct; 46(5):395-409. PubMed ID: 31338634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein replacement therapies for rare diseases: a breeze for regulatory approval?
    Gorzelany JA; de Souza MP
    Sci Transl Med; 2013 Mar; 5(178):178fs10. PubMed ID: 23536010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Orphan Drug Act: an engine of innovation? At what cost?
    Rohde DD
    Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720
    [No Abstract]   [Full Text] [Related]  

  • 37. Hints on preparing successful orphan drug designation requests.
    Buday PV
    Food Drug Law J; 1996; 51(1):75-84. PubMed ID: 11794354
    [No Abstract]   [Full Text] [Related]  

  • 38. Despite surge in orphan drug designations, approvals still lag.
    Heger M
    Nat Med; 2011 Mar; 17(3):236. PubMed ID: 21383708
    [No Abstract]   [Full Text] [Related]  

  • 39. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
    Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
    J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.